Dersa 1% (Cream)

25 gm tube: ৳ 30.00

Medicine Details

Category	Details
Generic	Silver sulfadiazine
Company	Marker pharma ltd

Topical prophylaxis against bacterial colonization and infection in burn wounds
Topical antibacterial management of contaminated or infection-prone wounds other than burns

Mechanism of Silver Sulfadiazine's antibacterial action not fully elucidated
Structural changes in bacterial cell membrane
Weakening of cell wall membrane
Reduced viability in sensitive strains
Silver sulfadiazine molecule dissociates and silver moiety is bound to bacterial cells
Prevents bacterial cell proliferation by attaching to DNA
Sulfadiazine moiety provides bacteriostatic action
Up to 10% of sulfadiazine may be absorbed in adults
Urinary excretion of absorbed sulfadiazine in adults is 60-85%
In children with 13% body surface area burns, urinary sulfadiazine concentration was 31.8 mg/L

Burn wounds are cleansed before application
Applied over the burn wound
Cover burn areas with Silver Sulfadiazine at all times
Applied once to twice daily at a thickness of approximately 1/16 inches or 1.5 mm
Reapplication needed if removed by patient activity
Use dressings if necessary
Reapply immediately after hydrotherapy
Treatment should continue until satisfactory healing occurs
Do not withdraw from therapeutic regimen if possibility of infection remains, except in case of significant adverse reaction

May inactivate enzymatic debriding agents
Concomitant use of enzymatic debriding agents may be inappropriate
Oral hypoglycemic agents and phenytoin action may be potentiated in large area burns
Blood levels of oral hypoglycemic agents and phenytoin may need monitoring in large area burns
Cimetidine co-administration may increase incidence of leukopenia in large area burns

Hypersensitivity to Silver Sulfadiazine or any other ingredients in the preparation
Pregnant women approaching or at term
Premature infants
Newborn infants during the first 2 months of life

Transient leukopenia reported
Other infrequently occurring events include skin necrosis, erythema multiform, skin discoloration, burning sensation, rashes, interstitial nephritis

Pregnancy Category B
Use during pregnancy only if clearly justified, especially in pregnant women approaching or at term
Unknown excretion of Silver Sulfadiazine in human milk
Decision to discontinue nursing or drug intake should be made considering importance of the drug to the mother
Safety and effectiveness in pediatric patients not established

Impaired hepatic and renal functions may cause drug accumulation
Discontinuation should be weighed against therapeutic benefit if elimination of drug decreases
Possibility of silver inactivating proteolytic enzymes should be noted when using topical proteolytic enzymes in conjunction with Silver Sulfadiazine
In patients with extensive burn wounds, serum sulfa concentrations may approach therapeutic levels
Monitor serum sulfa concentrations in these patients
Carefully monitor renal function and check urine for sulfa crystals